Sai Life Sciences IPO share allotment expected on Monday; Steps to check status online – CNBC TV18
| Company | Value | Change | %Change |
|---|
The IPO, which was open for subscription between December 11 to 13, saw overall subscription of 10.26 times. The price band for the issue was set at ₹522-549 per share.
Qualified Institutional Buyers (QIBs) led the demand for the issue, as their portion was subscribed to 30.93 times the total shares on offer. The portion reserved for non-institutional investors was subscribed 4.92 times, while retail investors portion was subscribed 1.37 times the total shares on offer for them.
Steps to check Sai Life Sciences IPO allotment status
Investors can verify their IPO allotment status using the websites of NSE, BSE or the IPO registrar, KFin Technologies.
Here’s how to check the share allotment status on the BSE website:
1. Visit the BSE IPO allotment page.
2. Select ‘Equity’ as the issue type.
3. Choose ‘Sai Life Sciences’ from the dropdown menu.
4. Enter your application number or PAN.
5. Click ‘Search’ to view your allotment status.
Here’s how to check the share allotment status on KFin Technologies’ website:
1. Go to the KFin Technologies IPO page.
2. Select ‘Sai Life Sciences’ from the dropdown menu.
3. Enter your PAN, application number, or DP/Client ID.
4. Click ‘Submit’ to check your status.
Successful applicants will receive shares in their demat accounts, while refunds will be processed for unsuccessful bids on December 17.
Sai Life Sciences IPO details
Sai Life Sciences raised ₹913 crore from anchor investors before the IPO opened for subscription.
The ₹3,043 crore IPO comprised a fresh issue of equity shares worth ₹950 crore and an Offer for Sale (OFS) of 3.81 crore shares, valued at ₹2,092 crore, by promoters, investor shareholders, and other stakeholders.
Of the funds raised, ₹600 crore will be allocated for debt repayment, with the remainder earmarked for general corporate purposes.
About Sai Life Sciences
Headquartered in Hyderabad, Sai Life Sciences provides comprehensive services across the drug discovery, development, and manufacturing value chain. The company specializes in small molecule new chemical entities (NCEs), catering to global pharmaceutical innovators and biotechnology firms.
